Abstracts tagged "Crystal-induced arthritis"

Abstract Number: 1134 • ACR Convergence 2025
Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
Pannathorn Nakaphan¹, Somkiat Phutinart², Patavee Pajareya², Priabprat Jansem³, Nattanicha Chaisrimaneepan⁴, Pim Jetanalin⁵ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ⁵Department of Medicine, Division of Rheumatology, University of Illinois College of Medicine, Chicago, IL
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an…
Abstract Number: 1131 • ACR Convergence 2025
Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance
Yuqi wang¹, Lingjiang Zhu¹, Jinshuo Han², Junbin Qian³, Martin Herrmann⁴, Jing Xue¹ and Lei Liu¹, ¹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ²Zhejiang University, School of Medicine, Hangzhou, China (People's Republic), ³Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ⁴University Hospital Erlangen, Erlangen, Germany
Background/Purpose: While aggregated neutrophil extracellular traps (aggNETs) constitute the primary structural component of tophi, the susceptible population for tophaceous gout remains poorly characterized. We investigated…
Abstract Number: 2588 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies
Angelo Gaffo¹, Herbert Baraf², Anand Patel³, Tuhina Neogi⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Ben Peace⁷, Hugues Santin-Janin⁸, Bhavisha Desai⁹ and Naomi Schlesinger¹⁰, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Boston University School of Medicine, Boston, MA, ⁵Global MACD, Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Statistical Science, Sobi, Stockholm, Sweden, ⁸Sobi, BASEL, Switzerland, ⁹Sobi, Glastonbury, CT, ¹⁰Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Urate-lowering therapy is recommended to lower serum urate (sUA) and for long-term prevention of gout flares (FitzGerald et al. Arthritis Care Res (Hoboken) 2020;…
Abstract Number: 1128 • ACR Convergence 2025
Association between leptin levels, body mass index and health-related quality of life in patients with gout
Inna Orlova¹, Iryna Shapoval², Nataliia Shkolina¹, Nataliia Kuzminova¹ and Mykola Stanislavchuk³, ¹National Pirogov Memorial Medical University, Vinnytsya, Vinnytsya, Ukraine, ²National Pirogov Memorial Medical University, Vinnytsya (Ukraine), Vinnytsya, Ukraine, ³National Pirogov Memorial Medical University, Vinnytsia, Vinnytsia, Ukraine
Background/Purpose: Gout is s a disease with a high disability rate, resulting in severe social burden and is associated with reduced health-related quality of life…
Abstract Number: 2587 • ACR Convergence 2025
Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
Puja Khanna¹, Amar Majjhoo², Rehan Azeem³, Ben Peace⁴, Bhavisha Desai⁵ and Vibeke Strand⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Shores Rheumatology, St. Clair Shores, MI, ³Global MACD, Sobi Inc., Waltham, MA, ⁴Statistical Science, Sobi, Stockholm, Sweden, ⁵Sobi, Glastonbury, CT, ⁶Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Patients (pts) with uncontrolled gout (UG; persistent elevation in serum uric acid [sUA] levels and clinical manifestations despite oral urate-lowering therapy) have poor health-related…
Abstract Number: 1126 • ACR Convergence 2025
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
Coralie Tremblay¹, Nathalie Carrier², Hugues Allard-Chamard³, Javier Marrugo⁴, Sophie Roux⁴, Gilles Boire⁵ and Ariel Masetto⁴, ¹Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Saint-Augustin-de-Desmaures, QC, Canada, ²Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ³Université de Sherbrooke, Sherbrooke, Canada, ⁴Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Sherbrooke, Canada, ⁵Retired, Sherbrooke, QC, Canada
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common cause of arthropathy over the age of 60. It can also manifest as a chronic polyarticular…
Abstract Number: 0281 • ACR Convergence 2024
Intra-articular Treatment Combining Sustained Release Colchicine Encapsulated in Microspheres, and Ropivacaine, Is Effective in Inflammatory Arthritis in Rats
Julien GRASSOT¹, Farah MARZOUKI², Roxane HERVE³, Magali BECKLER⁴, Luca SEMERANO⁵, Natacha BESSIS⁶, Elodie RIVIERE⁷, Charles SANSON², Gauthier POULIQUEN², Philippe POULETTY⁸ and Marie-Christophe BOISSIER⁹, ¹PK MED, LYON, Rhone-Alpes, France, ²PK MED, LYON, France, ³INSERM U1125, Bobigny, France, ⁴INSERM 1125, Bobigny, France, ⁵Avicenne Teaching Hospital APHP, Bobigny, France, ⁶INSERM, Université Sorbonne Paris Nord, PARIS, France, ⁷INSERM, Université Sorbonne Paris Nord, APHP, PARIS, France, ⁸PK MED, PARIS, France, ⁹University Sorbonne Paris Nord, Bobigny, France
Background/Purpose: Gout is a common disease with a prevalence and incidence on the rise worldwide. However, approved treatments to treat acute gout flares have slow…
Abstract Number: 0282 • ACR Convergence 2024
Electronic Health Record-Based Calcium Pyrophosphate Deposition Disease Registry: A Feasibility Study
Nils Bürgisser¹, Denis Mongin², Samia Mehouachi², Delphine Sophie Courvoisier³ and Kim Lauper⁴, ¹Division of Rheumatology and internal medicine, Geneva University Hospital, Switzerland, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland, ³Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ⁴Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Despite its prevalence, calcium pyrophosphate deposition disease (CPPD) remains insufficiently studied. Leveraging electronic health record (EHR) data, a rich source of patient information, could…
Abstract Number: 0284 • ACR Convergence 2024
Identification of Calcium Pyrophosphate Deposition Using Ultrasonography in Patients with a Suspected Diagnosis of Seronegative Rheumatoid Arthritis
Joanna Potera¹, Angelo Gaffo², Alvin Day³, Mariana Urquiaga² and Amanda Alexander⁴, ¹University of Alabama at Birmingham, Irondale, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Dept. of Veterans Affairs, Lexington, SC, ⁴University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Calcium pyrophosphate deposition disease is a common condition that can cause chronic polyarticular inflammatory joint disease, which sometimes resembles rheumatoid arthritis. Misdiagnosis is especially…
Abstract Number: 1071 • ACR Convergence 2024
Rapid Access Microscopy and Real Time Case Discussion via a Secure Messaging App Improves Diagnostic Accuracy and Management of Acute Hot Swollen Joints
Anouchka Lewis¹, John Stack², Oisin Corish², Callum Swift², Tomás Breslin², Frank Lyons², Eavan Muldoon², Cian McDermott², Sharon Cowley², Helina Alemayehu², Oliver Boughton², Khaled Taha² and Geraldine McCarthy², ¹The Mater Misericordiae University Hospital, Dublin, Ireland, ²Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with acute swollen joints are often presumed to have septic arthritis, leading to treatment with intravenous antibiotics and arthroscopic washout. Previously at our…
Abstract Number: 1083 • ACR Convergence 2024
Comparison of a Handheld Ultrasound Device with Cart-Based Ultrasound for the Assessment of Gout Lesions in People with Established Gout
Rachel Murdoch¹, Lene Terslev², Julia Martin³, Borislav Mihov¹, Gregory Gamble¹, Søren Torp-Pedersen⁴, Anne Horne¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ³Te Whatu Ora Te Toka Tumai, Auckland, New Zealand, ⁴Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Ultrasound is frequently used in rheumatology practice to assist with the diagnosis of rheumatic and musculoskeletal diseases. In patients with gout, it allows visualization…
Abstract Number: 1092 • ACR Convergence 2024
Chronic Kidney Disease Is Associated with Increased Glucose Uptake-associated Metabolic Activity of Visceral Adipose and Subcutaneous Adipose Tissue in Gout Patients
Shunya Kaneshita¹, Sho Fukui², Soheil Niku³, KWANGHOON LEE⁴, Ernest Belezzuoli³, Robert Terkeltaub⁵ and Monica Guma⁶, ¹UCSD, Miyazu city, Kyoto, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³UCSD, La Jolla, ⁴UCSD, San Diego, CA, ⁵Retired, San Diego, CA, ⁶UCSD, La Jolla, CA
Background/Purpose: Gout, a condition characterized by elevated uric acid levels, is linked to multiple complications, including coronary artery disease, hypertension, and type 2 diabetes mellitus.…
Abstract Number: 1094 • ACR Convergence 2024
Longitudinal Analysis of Serum Urate in Prediabetic Phase
Javier Marrugo¹, Leah Santacroce¹, Misti Paudel², Sho Fukui³, Sara Tedeschi¹ and Daniel Solomon⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: More than 460 million people worldwide are currently living with prediabetes, a condition that not only predisposes individuals to diabetes (DM) but also to…
Abstract Number: 1095 • ACR Convergence 2024
The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study
Shay Brikman¹, Amir Bieber², Liel Serfaty, MA³, Ran Abuhasira, MD, PhD⁴, Nadav Rappoport⁵ and Naomi Schlesinger⁶, ¹Emek Medical Center, Afula, Israel, ²Emek Medical Center, Clalit Health Services, Raanana, Israel, ³Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ⁴Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶University of Utah, Salt Lake City, UT
Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…
Abstract Number: 1103 • ACR Convergence 2024
The Role of Renal Dual-Energy CT in Exploring the Gouty Kidney: The RENODECT Study
Tristan Pascart¹, Elie Dauphin¹, Chio Yokose², Charlotte Jauffret³, Hyon K. Choi⁴ and Jean-François Budzik⁵, ¹Université Catholique de Lille, Lille, Nord-Pas-de-Calais, France, ²Massachusetts General Hospital, Boston, MA, ³Lille Catholic University, Lille, Nord-Pas-de-Calais, France, ⁴Massachusetts General Hospital, Lexington, MA, ⁵Lille Catholic University, Lille, France
Background/Purpose: Chronic kidney disease (CKD) is a common feature in gout, and can have multiple causes, some of which are gout specific, such as gout…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].